N/A
N=17
Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Hypoglycemia
Bottom Line
View on ClinicalTrials.gov: NCT01462227 ↗Enrolled (actual)
17
Serious AEs
0.0%
Results posted
Feb 2016
Primary outcome: Primary: Glucose (mg/dL) — 56.5; 52.8; 55.0; 52.8 mg/dL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Naltrexone High Dose (Drug); Naltrexone Low Dose (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Yale University
- Primary completion
- Oct 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glucose (mg/dL) |
56.5; 52.8; 55.0; 52.8 | — |
| PRIMARY Glucose Infusion Rate (mg/kg.Min) |
4.6; 6.3; 4.8; 5.9 | — |
| SECONDARY Glucagon (pg/mL) |
44.1; 48.9; 40.4; 53.6 | — |
| SECONDARY Cortisol (ug/dL) |
22.9; 16.4; 16.0; 15.2 | — |
| SECONDARY Epinephrine (pg/mL) |
92.75; 126.1; 42.75; 77.9 | — |
| SECONDARY Norepinephrine (pg/mL) |
248.3; 200.1; 282.8; 217.1 | — |
Summary
Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Currently there are no therapeutic agents that can be used to improve the recovery from hypoglycemia (low blood sugar). Naltrexone is a tablet used to help people who are addicted to alcohol or morphine-based drugs to remain drug and alcohol-free but it can also affect the levels of the hormones which are released during hypoglycemia. The aim of this study is to determine whether naltrexone can be used to improve and accelerate the recovery from hypoglycemia in patients with type 1 diabetes.
Eligibility Criteria
Inclusion Criteria
- type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk) age 18-55, BMI 18-35
Exclusion Criteria
- pregnancy
- significant diabetes complications
- liver disease, cirrhosis
- cardiac disease
- neurological disorder
- autonomic neuropathy
- kidney disease
- lactose intolerance
Data sourced from ClinicalTrials.gov (NCT01462227). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.